Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Net Current Asset Value 2 year CAGR for the year ending December 31, 2022: -62.65%

Freeline Therapeutics Holdings Plc Net Current Asset Value 2 year CAGR is -62.65% for the year ending December 31, 2022, a -438.35% change year over year. Net current asset value is a financial metric that represents the excess of a company's current assets over its total liabilities. It is calculated by subtracting the total liabilities from the total current assets of a company. Net current asset value provides insights into the value that would be available to shareholders if the company were to liquidate its current assets and pay off its liabilities. This metric is used to assess the company's liquidity position and the potential value for shareholders in a liquidation scenario. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Freeline Therapeutics Holdings Plc Net Current Asset Value for the year ending December 31, 2022 was 33,400,000.00, a -68.96% change year over year.
  • Freeline Therapeutics Holdings Plc Net Current Asset Value for the year ending December 31, 2021 was 107,608,000.00, a -55.04% change year over year.
  • Freeline Therapeutics Holdings Plc Net Current Asset Value for the year ending December 31, 2020 was 239,364,000.00, a 212.44% change year over year.
  • Freeline Therapeutics Holdings Plc Net Current Asset Value for the year ending December 31, 2019 was 76,612,000.00, a 352.63% change year over year.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email